Garry Menzel, TCR² CEO

TCR² re­leas­es ear­ly da­ta from some PhI pa­tients, spark­ing op­ti­mism from an­a­lysts

A lit­tle over a year and a half since its $100M-plus IPO, im­munother­a­py biotech TCR² Ther­a­peu­tics $TCRR re­leased the first da­ta from Phase I/II tri­als for its lead T cell ther­a­py to­day, with some an­a­lysts ex­press­ing op­ti­mism from the re­sults.

Though the sam­ple size is small, the da­ta from five pa­tients in the Phase I por­tion showed that none of the five in­di­vid­u­als ex­pe­ri­enced neu­ro­tox­i­c­i­ty or on-tar­get, off-tu­mor tox­i­c­i­ties, a pri­ma­ry goal in the tri­al. Cy­tokine re­lease syn­drome man­i­fest­ed in three of the pa­tients, with one dy­ing a lit­tle over a month af­ter treat­ment due to an un­re­lat­ed fun­gal sep­sis.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.